Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Opsumit
Pharma
J&J dumps Opsumit trial upon pulmonary hypertension flop
Janssen has pulled the plug on a phase 3 trial of high-dose Opsumit, losing a chance to challenge Bayer's Adempas in a pulmonary hypertension subtype.
Angus Liu
Sep 7, 2023 11:03am
In PAH patients, J&J's combo pill Opsynvi increases blood flow
Mar 6, 2023 9:37am
Remicade and Xarelto woes haven't stopped J&J hiking forecast
Apr 17, 2018 12:19pm
Special Report—The top 10 cardiovascular drugs in the world
Aug 28, 2017 7:00am
Actelion's Opsumit fails key study as J&J megadeal nears
Jan 23, 2017 9:13am
'Audacious' CVS drops key meds from Sanofi, Novartis and more
Aug 3, 2016 6:22am
